Human neutrophil (PMN) attachment to human umbilical vein endothelial cells (HUVEC) was evaluated in vitro using two MAbs, R6-5-D6 and RRi/1, that recognize intercellular adhesion molecule-i (ICAM-1), and one MAb, TS1/18, that recognizes CD18. Pretreatment of the HUVEC with anti-ICAM-1 MAbs produced > 50% inhibition of attachment to HUVEC, and IL-1 (0.5 U/ml)-or lipopdysaccharide (LPS) (10 ng/ml)-stimulated HUVEC, and > 99% inhibition of f-Met-Leu-Phe (0.5 nM) enhanced adherence. Anti-ICAM-i MAbs also inhibited by > 85% the transendothelial migration induced by 4-h IL-1 (0.5 U/ml) and LPS (10 ng/ml) activation of the HUVEC. That these effects involved a CD18-dependent mechanism is supported by the following results: pretreatment of PMN with TS1/18 produced the same degree of inhibition of attachment and migration as seen with R6-5-D6. In addition, the use of both MAbs together did not further increase the inhibition of cell attachment to stimulated HUVEC. The attachment of PMN from patients with CD18 deficiency to stimulated HUVEC was not reduced by R6-5-D6, and both R6-5-D6 and TSI/18 revealed the same time course for appearance and disappearance of an adherence component on stimulated HUVEC not blocked by either MAb. These results demonstrate that attachment and transendothelial migration of PMN in vitro depend substantially on both CD18 on the PMN and ICAM-1 on the endothelial cell.
Introduction
Interaction with endothelial cells is fundamental to the localized infiltration of neutrophils and monocytes into extravascular inflammatory sites (1, 2) or the homing of lymphocytes to lymphoid organs (2) (3) (4) . Recent experimental and clinical observations have begun to define the molecular determinants on the surface of leukocytes that contribute to the adhesive component ofthis interaction (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . The most convincing clinical evidence has accrued from studies ofthe heritable disorder (14, 15) termed leukocyte adherence deficiency disease (LAD)' (14) . Characteristic features of patients with LAD including necrotic soft tissue lesions, impaired pus formation and wound healing, as well as abnormalities of adhesion-dependent leukocyte functions in vitro, are attributed to a severe or total deficiency of the glycoprotein, CD18 (14, 15) .
The CD 18 complex consists of three heterodimers, Mac-1 (iC3b receptor), lymphocyte function-associated antigen-1 (LFA-1) and p 150,95, each of which consists of noncovalently associated a and fi subunits with a,3, stoichiometry. They share an identical ,B subunit (Mr = 95,000 kD) and are distinguished immunologically by distinct a subunits whose relative molecular masses are 165,000, 177,000, and 150,000 kD for Mac-I (aM, CD I l b), LFA-I (aL, CD I l a), and p 150,95 (aX, CD 1 I c), respectively. That these heterodimers are involved in the adherence of leukocytes to endothelial cells is clearly demonstrated by the fact that leukocytes from patients with LAD exhibit profoundly reduced adherence to endothelial monolayers in vitro (16, 17) as well as by the absence ofleukocytes in infected tissues of these patients (14, 15) . Additional evidence for the involvement of these heterodimers comes from the use of subunit monoclonal antibodies. Endothelial adherence of lymphocytes and monocytes in vitro is inhibited by pretreatment of these leukocytes with MAbs reactive with LFA-1 or the f subunit. The enhanced adherence ofneutrophils to endothelium in vitro caused by exposure of the neutrophils to chemotactic or degranulating stimuli is inhibited by pretreatment ofthe neutrophils with MAbs reactive with either Mac-1 or the f3 subunit (10, (16) (17) (18) (19) (20) .
The endothelial surface factors with which the CD 18 complex on neutrophils and monocytes is interacting appear to be induced by exposure of the endothelial cells to the inflammatory mediators, endotoxin (lipopolysaccharide, LPS), interleukin 1 (IL-1), and tumor necrosis factor-a (TNFa) (20, 21 ). An important recent finding regarding cytokine-induced adherence factors involves the identification of a ligand for LFA-I on a variety of human cell types. A MAb (RRl/ 1) prepared against CDl 8-deficient human lymphoblasts has been identified which inhibits aggregation of normal lymphocytes (22) . This MAb recognizes a normal cell surface molecule distinct from LFA-1 that is designated intercellular adhesion molecule 1 (ICAM-1). Recently reported studies (23) have shown that ICAM-1 participates in the adhesive interactions of multiple leukocyte cell types, including transformed B cells, myeloid cell lines, and T lymphocyte blasts. It was also found on nonlymphoid cells, including thymic epithelium, dendritic cells in germinal centers, and cultured fibroblasts and endothelial cells. Further characterizations of ICAM-1 have demonstrated its enhanced expression on vascular endothelium or dendritic cells in germinal centers of inflamed lymphoid tissues. ICAM-1 expression on dermal fibroblasts or endothelial cells is greatly enhanced by either interleukin 1 (IL-1) or interferon-y (23, 24) . Induction is dependent upon protein and mRNA synthesis and is reversible. Importantly, intercellular adhesion of lymphocytes to fibroblasts is enhanced by prior IL-1 exposure and is blocked by the monoclonal antibody reactive with ICAM-1 (RR 1/1). Moreover, normal lymphocytes demonstrate an enhanced adherence to vascular endothelium preexposed to IL-1, TNF or interferon--y, and this increased adhesive property is directly correlated with ICAM-1 expression. Thus, ICAM-1 or ICAM-1-like molecules (16) exist on vascular endothelium and other mesenchymal cell types which appear to represent selective ligands for LFA-1 (25, 26) and possibly other glycoproteins in the CD1 8 complex, and are under the influence of a variety of inflammatory mediators.
In this report, by utilizing a newly developed monoclonal antibody reactive with ICAM-1, R6-5-D6, we present the first direct evidence of a human endothelial cell determinant of major importance in the CDl 8-dependent human neutrophil adherence to endothelial cells. Our findings indicate that this determinant is necessary for the migration of human neutrophils through endothelial monolayers. Additionally, we describe some characteristics of a CD1 8-and ICAM-1-independent mechanism for attachment of neutrophils to endothelial cell monolayers that also appears to be involved in transendothelial migration.
Methods
Isolation ofPMN. PMN obtained from healthy adult individuals and two patients with a severe form of CD1 8 deficiency (27) were purified from citrate-anticoagulated, dextran-sedimented venous blood samples over Ficoll-Hypaque gradients and were suspended in Dulbecco's phosphate-buffered saline (PBS; Gibco, Grand Island, NY), pH 7.4, containing 0.2% dextrose as described (28) . PMN were maintained at 40C in PBS for up to 4 h at a concentration of 107/ml.
MAbs. MAbs used in these studies included dilutions of ascites fluid, preparations of IgG, and Fab fragments. The anti-# MAb was TSI/1 8 (IgG 1) a generous gift of Dr. T. Springer, Dana-Farber Cancer Institute, Boston (29) . R6-5-D6 (IgG2a) was developed by fusing spleen cells from mice immunized with a battery of ICAM-I -bearing cell lines. Its profile ofreactivity in lymphoblast aggregation assays and the molecular weight of its immunoprecipitated antigen on JY cells are identical to RR I/l anti-ICAM-l (22, 23) . The anti-HLA framework MAb was W6/32 (IgG2a) (30, 31) .
Preparation of human umbilical vein endothelial cells (HUVEC).
HUVEC were harvested (32, 33) and characterized as to acLDL binding (34) and factor VIII expression (32) according to established techniques. Cells from 5-10 umbilical cords were pooled and plated in RPMI 1640 containing 10% fetal calf serum (FCS), antibiotics, heparin (0.1 mg/ml), and endothelial cell growth factor (0.05 mg/ml), and maintained for 3-4 d at 37°C, 5% C02-humidified atmosphere. Visually confluent monolayers on gelatin (0.1 %)-and fibronectin (5 yg/cm2)-coated 25-mm round glass coverslips were prepared from first-passage cells harvested with 0.05% trypsin and 0.02% EDTA in PBS. Monolayers in fibronectin (5 'tg/cm2)-coated 96-well microtiter plates were prepared from first-and second-passage cells and grown to confluence (1-3 d) . HUVEC were pretreated with various concentrations of LPS (Sigma Chemical Co., St. Louis, MO. Escherichia coli 026:B6), or IL-I (Genzyme Corp., Boston, MA; cell derived) for varying lengths of time.
Adherence assay. A visual adherence assay was utilized as previously described (35) with the exception that adherence to HUVEC monolayers was assessed instead of adherence to protein-coated glass.
HUVEC monolayers on 25-mm round glass coverslips were washed by dipping three times in two changes of PBS and immediately inserted into the adherence chambers specifically made for use with an inverted microscope and phase-contrast optics. The chambers consisted of two metal plates designed to hold two 25-mm round cover glasses separated by a Sykes-Moore chamber 0-ring (Bellco Glass, Inc., Vineland, NJ). Within this closed compartment PMN could be observed as they contacted the HUVEC monolayer. PMN suspended in PBS (1O6 cells/ ml) or pretreated with low concentrations of fMLP (35) (36) (37) (38) (39) (40) were injected into the chamber and allowed to settle onto the monolayer for a period of 500 s. The number of PMN in contact with the monolayer was determined by counting at least 10 microscopic fields (X 50 objective), and the chamber inverted for an additional 500 s. The percentage of cells remaining in contact with the monolayer was determined and is expressed in Results as percent adherence. In blocking experiments, HUVEC were pretreated with MAbs for 15 min then washed three times by dipping in two changes of PBS prior to evaluating adherence.
PMN were pretreated for 5-15 min, and then injected into the adherence chamber in most instances without washing. It should be noted that the procedure used in this study does not utilize shear stress (41) (42) (43) as with techniques requiring a washing step (10, (16) (17) (18) (19) (20) (21) . Rather it simply assesses attachment.
The percentage of cells migrating through the monolayer was also determined using criteria previously developed by Beesley et al. (44) . Using phase-contrast otics, PMN adherent to endothelium are round and appear refractile with a surrounding halo since they do not spread on the surface of endothelial cells (45) . In contrast, the leukocytes become quite flattened after migrating to a position between the monolayer and the substratum (46) , and they lose the refractile appearance (44) . Intracellular granules are readily seen. The focal plane for these leukocytes is beneath the nuclei of the endothelial cells and that for the PMN adherent to the upper surface of the monolayer is unequivocally above. Other direct demonstrations of transendothelial migration were provided by sections of HUVEC monolayers embedded in epoxy resin. HUVEC monolayers grown on human amnion for 8 d (47, 48) were stimulated with 0.5 U/ml IL-l for 4 h at 370C, then washed by dipping in PBS. PMN suspended in PBS at 106/ml were allowed to contact the monolayers for 1,000 s before the membrane was submerged in 1% glutaraldehyde in PBS for 1 h, rinsed in PBS, dehydrated, and embedded. Sections were stained with 1% methylene blue, 1% Azure II in 1% sodium borate.
Assessment ofMAb binding to cells. Immunofluorescence flow cytometry was performed as previously described (49) RRl/l ascites fluid was employed. Similarly, the last immunoprecipitate was accomplished with R6-5-D6. Aliquot III was treated similarly except no antibody was added until the last cycle, when 5 Ml of R6-5-D6 was used. SDS-PAGE and autoradiography (7.5% acrylamide) was performed as described for HUVEC.
HUVEC were grown to confluency in tissue culture flasks and incubated with 20 ng/ml LPS for 2 h. The monolayers were washed twice with RPMI 1640 deficient in both methionine and cysteine supplemented with 20% FCS. After a 1-h incubation in this deficient medium, 1 mCi of [35S]cysteine and 0.5 mM unlabeled methionine was added for 10 min at 37°C. The monolayers were then rinsed and incubated in RPMI 1640 containing methionine and cysteine supplemented with 20% FCS for 1 h at 37°C. After washing the cells in RPMI 1640 three times, lysis buffer (borate buffered saline, 0.5% Triton X-100, 0.05% Tween, 1% BSA, and 2 mM PMSF, pH 8.0) was then added to solubilize the cells. Nuclei and cell debris were pelleted at 12,000 g for 10 min. The supernatant was then precleared by the addition of protein A bound to Sepharose CL-4B (Sigma Chemical Co.). After removal ofthe protein A-Sepharose beads, 5 ,ul of R6-5-D6 ascites fluid was added and the mixture allowed to incubate at 4°C for 30 min. Protein A bound to Sepharose CL-4B was then added to the mixture and tipped for 1 h at room temperature. The Sepharose beads were washed three times with 0.1% NP-40 and placed in SDS sample buffer containing 2.5% SDS and 5% (wt/vol) mercaptoethanol, and boiled for 2 min. SDS-PAGE (7.5% acrylamide) and autoradiography were performed as previously described (50 HUVEC were incubated for 4 h, 370C, in the presence of the indicated concentrations of IL-I and then washed by dipping three times in two exchanges of PBS. The adherence of unstimulated PMN suspended in PBS was then determined using a visual assay performed at room temperature. The effect of fMLP was determined by suspending PMN in the indicated concentrations of fMLP and incubating for 5 min at room temperature before determining adherence to unstimulated HUVEC using a visual assay performed at room temperature. Error bars, ±SD; n = 4; P < 0.01 for all points beyond 0.05 nM fMLP and 0.01 U/ml IL-1.
81.2+7.4%; n = 21). Near maximal adherence was attained at 10 ng/ml LPS (80.1±7.6%; n = 25). Each of the latter two stimuli promoted 100% adherence after a 4-h incubation with the HUVEC provided the concentrations exceeded 2 U/ml IL-I or 30 ng/ml LPS. (31) . R6-5-D6, RRl/l, and W6/32 bound to HUVEC. The EIA procedure using an alkaline phosphatase-labeled anti-mouse antibody revealed that exposure of HUVEC to 20 ng/ml LPS resulted in a four-to fivefold increase at 4 h and five-to sevenfold increase at 7 h in binding of R6-5-D6, and RRl/l. W6/32 binding was not increased at 4 h, and at 24 h the increase was < 20%.
Immunofluorescence (IF) microscopy revealed a uniform distribution of R6-5-D6 and RRl/l over the surface of each endothelial cell after paraformaldehyde fixation. In the unstimulated monolayer, all cells exhibited fluorescence with about 20% obviously staining brighter than the average cell. After a 4-h stimulation with IL-1 (0.5 U/ml) or LPS (10 ng/ml) the overall intensity of the fluorescence was increased on all cells and -50% were distinctly bright. Under maximum resolution (X 100 objective) the fluorescence was seen to be punctate with a uniform spacing of < 0.5 gm. IF Immunoprecipitation ofan endothelial cell glycoprotein by R6-5-D6. The reaction of R6-5-D6 with ICAM-1 was confirmed in co-immunoprecipitation experiments with RRl/l. Prior immunoprecipitation with either antibody greatly depleted the JY cell lysates of antigen reactive with the other antibody. As has been previously observed, the molecular weight of ICAM-1 obtained from JY cells is lower than that from endothelial cells and fibroblasts (23) . SDS-PAGE of NP-40 lysates ofHUVEC treated with LPS, pulse-labeled with [35S]cysteine, and immunoprecipitated with MAb R6-5-D6 revealed a single band at Mr = 95,000 kD (Fig. 3) . As with the JY cell lysates, immunoprecipitation with R6-5-D6 cleared the lysate of antigen reactive with RRl/l (Fig. 3) .
Effects ofMAbs on adherence: pretreatment ofPMN. Incubation of the PMN with TS 1/ 8 revealed maximal inhibition of adherence at a 1:800 dilution of ascites fluid and at 5 ,g/ml of the IgG preparation. As shown in Fig. 4 (Fig. 4) bound to HUVEC increased markedly over the first 3 h and remained high over the 8 h of observation as revealed by the EIA procedure (Fig. 8) . This was in contrast to the changes seen in adherence of unstimulated PMN over the same time period (Fig. 2) . The diminishing adherence seen after 4 h stimulation of HUVEC with IL-l or LPS apparently could not be accounted for by reductions in the amount of the endothelial surface factor recognized by R6-5-D6. Therefore, the contribution ofthe CDl 8-independent determinants ofPMN adherence was evaluated. Adherence of PMN pretreated with saturating concentrations of TSl/1 8 to LPS (Fig. 8) (Table IV) . When the stimulus to the endothelial cells was sufficient to promote adherence of 99% of the PMN in the absence of added chemotactic factors, the contribution of CD18 to this adherence was only about 25%.
Requirementsfor PMN migration through HUVEC monolayers. As has been observed by others (37, 44, 46, 51, 52) , a portion of the PMN adherent to the HUVEC moved through the monolayer and migrated between the HUVEC and the substratum. These neutrophils assumed the bipolar configuration typical of motile PMN, though in marked contrast to the cells attached to the upper surface of the monolayer, they appeared greatly flattened within this space. Movement through the monolayer was quantitated using phase contrast observations of the monolayer en face. This was possible because of the morphologic change and the distinct difference in focal planes ofthe cells on the surface ofthe monolayer versus those beneath (Fig. 10 A) . It was often possible to discern the uropod ofmigrating cells protruding through the monolayer before the cell fully traversed the thickness of the monolayer (Fig. 10 A) . Cross sections of monolayers confirmed this transendothelial migration and revealed protruding uropods (Fig. 10 B) .
The percent PMN exhibiting this behavior was very low under baseline conditions (< 1%; n = 45) or exposed to fMLP (Fig. 1 1) . However, when stimulated for 4 h with IL-I or LPS, the per through the monolayer increased significant] = 25; 10 ng/ml LPS; Table IV; Fig. 11 ). WE assay was performed at 370C, this behavior c monolayers was exhibited by a significantly M of the cells (78.4±4.2%; n = 8; P < 0.01), tI adherence was increased less by this increa- (Fig. 12) . In contrast to the results witi HUVEC, migration through the monolayer ' the HUVEC were used 8 h after stimulation IL-1. R6-5-D6 and TS1/18 were both eq IL-1 stimulated (0.5 U/ml) monolayers was 30.6±12.6% (n jually effective in = 17) compared to 1.6±1.6% (n = 17; P < 0.01) when PMN were preincubated in TS1/18 (1:400 dilution of ascites), or Idherence to LPS-2.5±1.7% (n = 6; P < 0.01) when the HUVEC monolayer was -y Activity ofMAbs preincubated with R6-5-D6 (1:400 dilution of ascites). When adherence and migration were heightened by increasing the concentrations of the stimulus to the endothelial cells, TS 1/18 was very effective in blocking migration (Table IV) 
Discussion
The human endothelial determinant recognized by the MAb, R6-5-D6, appears to be of major importance in the CDI 8-dependent adherence of human neutrophils to HUVEC in vitro. This conclusion obviously depends on a direct, reliable documentation of CD118-dependent PMN adherence to HUVEC. 1752 Smith et al. exhibited low levels of adherence and there was no enhancement after stimulation with chemotactic factors (16, 17 (24, 56) . Also, the same stimuli induce its expression (e.g., IL-1 and LPS). Support for the possibility that the endothelial activation antigen plays a role in PMN adherence comes from the observation that one of the MAbs (H 18/7) partially inhibits neutrophil adherence to stimulated HUVEC (57) . The relationship ofthis mechanism to the CD18-independent adherence observed after stimulation of HUVEC with a-thrombin or LTC4 (19) (Fig. 3) . Additionally, the observations that RRl/ 1 inhibits adherence and transendothelial migration to the same degree as R6-5-D6, and the combination of both MAbs is no more effective than either alone supports this conclusion. In unpublished experiments, Dr. Steven D. Marlin (Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT) has found that although R6-5-D6 and RRl/l bind to ICAM-1, they bind to different epitopes. Thus, current evidence indicates that ICAM-1 is involved in CD I8-dependent adherence of PMN while the endothelial activation antigen involves another adherence mechanism on the PMN.
Migration of PMN beneath endothelial cell monolayers grown on protein-coated glass or plastic substrata has been repeatedly observed (37, 44, 46, 51, 52) . This migration occurs in the absence of added chemotactic stimuli and cannot be explained in terms of the relative adhesiveness of the endothelium and substratum (44) . Since the adherence assay utilized in the present study allowed direct determination of the percentage of migrating PMN, this phenomenon could be monitored with each experimental manipulation. Migration of unstimulated PMN to a position between the HUVEC monolayer and the substratum occurred in a high percentage of PMN only when the HUVEC monolayer was stimulated with LPS or IL-1. This percentage increased substantially when the adherence assay was performed at 37°C compared to the results at room temperature. It is of interest to note that a chemokinetic stimulus (i.e., fMLP present in the adherence chamber at a uniform concentration) did not promote this behavior in the PMN. The migration of unstimulated normal PMN beneath LPS-or IL-I-stimulated HUVEC monolayers was profoundly inhibited by the presence of TSl/l 8 
